Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Relypsa Are Climbing Today

By George Budwell - Jan 26, 2016 at 10:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma's shares briefly spiked today on a positive clinical update for the company's closely watched treatment for hyperkalemia.

What: Shares of biopharma company Relypsa (NASDAQ: RLYP) gained more than 11% right after the opening bell this morning on heavy volume. The stock's double-digit move upwards was triggered by the news that the company's FDA-approved treatment for elevated potassium levels (hyperkalemia) failed to show any clinically meaningful reductions in absorption levels when taken with 9 out 12 drugs tested in a series of small early-stage studies. Perhaps most encouragingly, these studies reportedly showed that all 12 drugs tested produced normal absorption levels if administered at least three hours apart from the treatment, called Veltassa. 

So what: Ever since Veltassa's approval last October, investors have been concerned about the drug's black-box warning outlining the potential for interactions with other orally administered medicines. Indeed, the stock has now fallen by nearly 50% from its 52-week highs, according to S&P Capital IQ:

RLYP Chart

RLYP data by YCharts.

The concern among Relypsa's shareholders is that this black-box warning for Veltassa could allow AstraZeneca's (AZN -0.39%) rival experimental drug, ZS-9, to capture the lion's share of this billion-dollar-plus market. After all, AstraZeneca has stated that ZS-9 didn't have any significant drug-drug interactions in its trials. 

Now what: The company now needs to consult with the FDA about the next steps toward getting this black-box warning lifted. Although this process could take several weeks, the good news is that Relypsa does have until May 26 before the FDA is scheduled to make a decision on AstraZeneca's regulatory application for ZS-9. 


George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.03 (-0.39%) $0.26
Relypsa, Inc. Stock Quote
Relypsa, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.